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doi:10.1016/j.ejvs.2008.01.015Abstract Objective: The aim was to describe the results of starting a foam sclerotherapy
service, focussing on patients with complicated venous disease.
Methods: Consecutive patients undergoing ultrasound-guided foam sclerotherapy for truncal
varicose veins underwent clinical and hand-held Doppler assessment at 2 weeks and venous
duplex imaging at 6 months.
Results: One hundred and eighty-five truncal veins were treated in 165 patients. A high propor-
tion of veins were complicated (109 CEAP classes 4e6, 76 CEAP 1e3). Ninety-one percent (168)
had a single treatment session. After 2 weeks, ninety-three percent (136/147) of the truncal
veins appeared occluded on hand-held Doppler examination. Ten percent (15/147) of patients
had remaining visible varicosities in the lower leg. After six months, the truncal vein remained
occluded in 74% (68/92), was partially occluded in 10% (9/92) and fully patent in 16% (15/92).
There was no significant difference in occlusion rates between: primary (45/60e75%) and
recurrent (23/32e72%) veins; CEAP 2e3 (22/30e73%) and CEAP 4e6 (46/62e74%) veins; veins
with diameter< 7 mm (29/38e76%) or 7 mm (13/23e57%). No patient had evidence of deep
vein thrombosis, though nine (10%) had new segmental deep venous reflux compared with pre-
treatment scans.
Conclusion: Foam sclerotherapy was equally effective for complicated and uncomplicated
varicose veins.
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Foam sclerotherapy is gaining in popularity in the United
Kingdom as a treatment for varicose veins. A questionnaire
in 2006 suggested it is currently being used by at least 70d by Elsevier Ltd. All rights reserved.
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Britain and Ireland1 Impressive 3 year follow-up results
have been reported in the literature2 and two recent large
case series by leading UK surgeons3,4 have further raised
the profile of foam sclerotherapy as a potential alternative
to standard surgery for varicose veins. The aim of the pres-
ent study was to describe the results of starting a foam ser-
vice in the setting of the National Health Service (NHS) in
Gloucester, UK. This report describes an initial experience.
Treatment was focussed on elderly patients unsuitable for
general anaesthesia with complicated varicose veins, and
the results of foam sclerotherapy in this group were
contrasted with patients with symptomatic uncomplicated
varicose veins who requested foam treatment.
Materials and Methods
Patients
Consecutive patients undergoing ultrasound-guided foam
sclerotherapy for truncal varicose veins at Gloucestershire
Royal Hospital, UK, between January 2005 and March 2007
were included in the study. Their details were recorded as
suggested by NICE guidelines for this new treatment.5 From
January 2005, patients referred with varicose veins were
offered foam sclerotherapy as an alternative to standard
surgical treatment or conservative management. Endove-
nous thermal ablation techniques were not available at
the hospital at that time. After full discussion of the avail-
able options, surgery tended to be selected by younger pa-
tients, particularly those with extensive or bilateral veins,
or those with strong cosmetic concerns. Included in the
study were patients having foam sclerotherapy for truncal
varicose veins, including the great saphenous vein (GSV),
small saphenous vein (SSV), anterior accessory saphenous
vein (AASV) or other recurrent veins with significant
proximal incompetent deep venous connection. A small
number of patients who had foam sclerotherapy for minor
superficial reticular varices were not included in this series.
Initial ultrasound assessment
The decision to intervene was made initially in outpatients
using hand held continuous wave Doppler ultrasound
examination. Patients who selected foam sclerotherapy
all underwent an initial venous duplex scan using an ATL
HDI 5000. They were examined sitting on the edge of an
examination couch with their legs dependent. Reflux was
defined as retrograde flow lasting for more than 1 sec in the
target vein after manual calf compression-release. The
scan assessed all deep, superficial and perforating veins.
The diameter of each incompetent saphenous trunk was
measured at a site estimated to be representative of over-
all size by the operator.
Foam sclerotherapy technique
At the initial treatment session, the primary aim was to
occlude the main incompetent truncal vein using the
method described by Coleridge-Smith (who provided uswith initial training and mentoring).3 Veins were cannu-
lated under ultrasound vision with an 18 G/20 G cannula
or butterfly-21 needle depending on size, depth and tortu-
osity. The GSV was routinely canulated immediately above,
or just below the knee. Often a second cannula or butterfly
needle was inserted more distally to treat the lower GSV or
calf tributary. Other truncal veins were cannulated at the
most distal point that they were still of sufficient size for
easy canulation. Foam was generated by the Tessari
method mixing 0.5 ml 3% sodium tetradecyl sulphate with
1.5 ml air via a three-way tap. The leg was elevated to
around 45 degrees throughout injection, and foam was in-
jected in 2 ml aliquots under ultrasound vision until foam
was seen to approach the saphenofemoral or deep vein
junction. Between injections the patient was encouraged
to plantar- and dorsiflex the ankle to increase deep vein
blood flow and speed neutralisation of any foam that
reached the deep vein. This did not impair the efficacy of
the foam sclerotherapy. A maximum volume of 12 ml
foam was used per treatment session and the most proximal
vein was always treated first. A Profore #1 Natural Padding
Bandage (10 cm 3.5 m, Smith & Nephew) was placed
along the length of the treated vein 4 layers thick and
secured in place with a Peha-Haft bandage. A thigh-length
Preventex anti-embolism stocking providing 14e17 mmHg
compression at the ankle was fitted over the bandages.
After 5 days these were removed by the patient and the
anti-embolism stocking alone was worn for the remainder
of the two weeks.
Follow-up
Patients were assessed routinely in the outpatient clinic
two weeks after treatment where target vein patency was
assessed by hand-held Doppler. Patients with remaining
visible varicosities or an obviously patent truncal vein were
offered further foam sclerotherapy, at their discretion.
A second assessment was offered after six months which
included a clinical review and repeat duplex imaging. The
treated truncal vein was classified at ultrasound examina-
tion as occluded, partially occluded or patent and
incompetent. An occluded vein had no identifiable patent
lumen and no detectable blood flow along a significant
proportion of its length. A partially occluded vein had
a small remaining lumen with detectable flow only in an
antegrade direction. A patent vein had remaining reflux
flow throughout its length.
Analysis
As recommended, data were collected prospectively and
stored on an Excel database.5 Where appropriate, statisti-
cal comparison of outcome results was done using Chi
squared testing.
Results
One hundred and sixty five consecutive patients had foam
sclerotherapy for truncal venous incompetence: 60 men
and 105 women. They had a median age of 62 years (range
25e93). One hundred and eighty five truncal veins were
Table 1 Occlusion rates six months after foam sclerother-
apy related to target vein
GSV SSV AASV Other Total
Occluded 48 (72%) 1 (20%) 12 (100%) 7 (88%) 68 (74%)
Partially
occluded
7 (10%) 2 (40%) 0 (0%) 0 (0%) 9 (10%)
Patent 12 (18%) 2 (40%) 0 (0%) 1 (12%) 15 (16%)
Total 67 5 12 8 92
GSV great saphenous vein; SSV small saphenous vein, AASV an-
terior accessory saphenous vein.
Mid Term Results of Foam Sclerotherapy 111treated: 121 GSV, 12 SSV, 28 AASV and 24 others. One
hundred and seventeen legs had primary varicose veins and
68 had recurrent disease; 109 were for complicated
varicose veins CEAP 4e6 and 76 for symptomatic uncom-
plicated veins CEAP 2e3.
The target veins had a median diameter of 6.5 mm
(range 2.1e17.3). Median diameters were similar for CEAP
4e6 veins (7 mm) and CEAP 2e3 veins (6 mm). A median
of 8 ml (range 2e14) foam was used in the main treatment
session. There was poor correlation between vein diameter
and the volume of foam needed to produce occlusion
(rZ 0.34, Fig. 1) Ninety-one percent (168) of patients had
a single treatment session, 15 required a second session
and 2 patients needed 3 sessions to achieve target vein
occlusion. Second sessions were required for failed initial
cannulation (nZ 5 legs), failure to occlude the proximal
vein (6) and residual distal varicosities in 4 legs. Of the
two patients that required three sessions, one had two
failed cannulation attempts, and one had failed cannula-
tion of distal residual varicosities at the second attempt.
Two weeks
A total of 147 legs were assessed at 2 weeks (dropout 12%).
After their first treatment session 136 (93%) veins appeared
occluded on hand-held Doppler examination. Fifteen legs
(10%) had remaining visible varices in the calf area. Early
complications included 3 injection-site ulcers (2%), thought
to be due to foamextravasation, and one ulcer frombandage
friction, all of which healed, and five episodes of temporary
visual disturbance (3%), that settled within a few minutes.
Six months
Seventy-six patients (92 legs out of a possible 112 that
reached six month follow-up e 84%) attended for a duplex
ultrasound scan at six months. The treated vein was
occluded in 68 legs (74%), partially occluded in 9 (10%),0
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Figure 1 Correlation between volume of foam needed to occand patent in 15 (16%). There was no significant difference
in the occlusion rates in the different truncal veins (Table
1). Nor was there any variation in occlusion rate between
primary (45/60e75%) or recurrent (23/32e72%) veins, or
with respect to the severity of the venous disease: CEAP
2e3 (22/30e73%) and CEAP 4e6 (46/62e74%). Occlusion
rates did not improve significantly with increasing experi-
ence: first 46 legs e 33/46 (72%), second 46e35/46 (76%).
Although there appeared to be a difference in occlusion
rate between veins <7 mm diameter (29/38e76%) and
those 7 mm diameter (13/23e57%), this was not statisti-
cally significant (p< 0.1, c2 test).
None of the legs had any clinical evidence of femoral or
popliteal deep vein thrombosis, or anything visible on deep
vein duplex imaging after six months, although one patient
had a symptomatic, thrombosed gastrocnemius vein. This
was treated with compression and warfarin anticoagula-
tion. Nine legs (10%), however, had new segmental deep
venous reflux that was not present before treatment,
although the significance of this is unknown. Sixty-seven
patients (73%) were pleased with the results of their foam
sclerotherapy at 6 months. Eleven legs (16%) had residual
skin staining and 2 (2%) described a significant worsening of
telangiectases.10 12 14 16 18 20
ein diameter (mm)
lude the vein and its diameter. (rZ 0.34, Spearman’s test).
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There is a number of new techniques available to treat
varicose veins that challenge conventional surgery.6 All
types of thermal ablation have occlusion rates above
90% and can be done under regional anaesthesia. All, how-
ever, also require additional treatment for residual non-
truncal veins e either phlebectomies or sclerotherapy.
Foam sclerotherapy alone is effective treatment for
both truncal and non truncal varicosities.3,7e9 Occlusion
rates in the present study were not as good as those of
the thermal ablation techniques, or surgery. Indeed they
were inferior to other reports where duplex follow-up
and reintervention were an integral part of the technique.
It appears that a significant recanalisation rate accounts
for the discrepancy between the occlusion rate at 2 weeks
(93%) and that at 6 months (74%), though there are limita-
tions in the information provided by continuous wave
Doppler ultrasound follow-up. Barrett et al. also saw
a similar recanalisation rate; 31% of their patients
required a second treatment at 3 months,7 but further
recanalisation did not develop beyond this time. Cavezzi
et al.8 state that retreatment is an integral component
of a policy of sclerotherapy. The long term results
published by Cabrera2 incorporated the use of subsequent
injections of superficial branches at follow-up sessions. It
is likely that optimal treatment will include repeat sclero-
therapy where the initial effect was inadequate. The
technique used in Gloucester has the advantage of lower
cost, since only a single trip for intervention was needed
in over 90% of patients. Further studies should assess
whether routine review and re-treatment improves qual-
ity of life and is cost effective.
The majority of patients treated in this series had
complicated venous disease, unlike many of those treated
in the published literature who have uncomplicated
varicose veins. This arose because our current practice
includes a large number of patients with venous ulcers
treated with four layer compression through a nurse led
clinic.10 Previous research suggested that standard varicose
vein surgery reduced the rate of venous ulcer recurrence in
this patient group.11 Many of the patients with venous
ulcers are elderly and infirm, and either reluctant or unfit
for surgery. Therefore these seemed an ideal group to start
a foam sclerotherapy service. Truncal vein occlusion rates
were 75% in this group of patients after six months. A num-
ber of authors have reported similar encouraging results
from foam sclerotherapy in these patients.12e15
As experience accumulated, a number of patients with
uncomplicated varicose veins requested foam instead of
surgery. The present study has shown no difference in
success rates at six months according to severity of venous
disease. Therefore optimising the results of foam in all
categories is important. Potential factors affecting outcome
were explored in the present analysis. There was no
difference in vein occlusion rates at 6 months before, or
after the first 30 treatments for any of the three clinicians
involved in delivering the service, suggesting at most,
a minimal effect of the learning curve for foam intervention.
Occlusion rates for the different veins were similar; small
saphenous vein occlusion rates were disappointing butrepresented such a small numbers that this should be
interpreted with care. A previous study suggested that
target vein size was not a factor in achieving a successful
outcome with foam sclerotherapy16 and Cabrera’s 3 year re-
sults were achieved in patients all having a saphenofemoral
junction diameter of >9 mm.2 Although there was not a sta-
tistically significant difference in occlusion rates between
veins greater and less than 7 mm diameter in this study,
the difference (57 vs. 76%) may be a reflection of the small
number of treatments. Cavezzi showed a similar trend to-
wards poorer occlusion rates in veins> 7 mm diameter.8
Satisfaction rates were high in patients who had foam
in this study, as with other reported groups.7,8,17 Satisfac-
tion appeared greatest in patients who had had previous
varicose vein surgery (88% were pleased e 28/32). Compli-
cations such as injection site ulcers, phlebitis and severe
skin staining, that adversely affect satisfaction rates,
were infrequent in the present study. Temporary injection
site ulcers have been reported by others in similarly small
numbers,8,13,18 as has temporary visual distur-
bance.7,8,12,18 The incidence of both reported in a large
multi-centre registry was much lower; however, this may
represent the problem of under-reporting common with
this type of data collection.19 Deep vein thrombosis is
another recognised complication of foam sclerother-
apy.7,8,13,18,19,20 Although symptomatic thrombus was
only seen in one gastrocnemius vein in the study, the
10% incidence of new segmental deep venous reflux seen
at 6 months is worthy of further study. The incidence of
skin pigmentation remaining at 6 months was similar to
that reported by Cabrera et al.,12 though it continues to
improve for up to 12 months.7 The phenomenon of wors-
ening telangiectases after foam sclerotherapy is unre-
ported, but known to occur after liquid sclerotherapy
where it is termed matting. It can also occur after stan-
dard varicose vein surgery.
Sclerotherapy has been shown to be a cost-effective
treatment for varicose veins.21 It remains the only genuine
outpatient intervention and its low cost and ease of admin-
istration mean that use in the NHS is likely to grow. Compli-
cations are few, and appear mostly self-limiting. As for any
new treatment, research now needs to focus on process, to
identify the safest and most effective technique and
treatment strategy.20 In particular the possible benefit of
routine review and retreatment needs to be established.Acknowledgements
The authors would like to thank the specialists who
mentored us as we started the foam programme: Philip
Coleridge Smith, Sue Topp, Simon Darke and Sara Baker.
The authors have no conflicts of interest to declare and
there was no specific funding required.
References
1 O’Hare JL, Earnshaw JJ. The use of foam sclerotherapy for
varicose veins: a survey of the members of the Vascular Society
of Great Britain and Ireland. Eur J Vasc Endovasc Surg 2007;34:
232e5.
Mid Term Results of Foam Sclerotherapy 1132 Cabrera J, Cabrera Jr J, Garcı´a-Olmedo. Treatment of varicose
long saphenous veins with sclerosant in microfoam form: long-
term outcomes. Phlebology 2000;15:19e23.
3 Coleridge-Smith P. Chronic venous disease treated by ultra-
sound guided foam sclerotherapy. Eur J Vasc Endovasc Surg
2006;32:577e83.
4 Darke S, Baker S. Ultrasound-guided foam sclerotherapy for the
treatment of varicose veins. Br J Surg 2006;93:969e74.
5 National Institute for Health and Clinical Excellence. Ultra-
sound-guided foam sclerotherapy for varicose veins. Available
from: http://guidance.nice.org.uk/IPG217; May 2007 [accessed
21.06.07].
6 Campbell WB. Varicose veins and their management. BMJ 2006;
333:287e92.
7 Barrett JM, Allen B, Ockelford A, Goldman MP. Microfoam ultra-
sound-guided sclerotherapy of varicose veins in 100 legs. Der-
matol Surg 2004;30:6e12.
8 Cavezzi A, Frullini A, Ricci S, Tessari L. Treatment of varicose
veins by foam sclerotherapy: two clinical series. Phlebology
2002;17:13e8.
9 Myers K, Jolley D, Clough A, Kirwan J. Outcome of ultrasound-
guided sclerotherapy for varicose veins: medium-term results
assessed by ultrasound surveillance. Eur J Vasc Endovasc Surg
2007;33:116e21.
10 Ghauri AS, Taylor MC, Deacon JE, Whyman M, Earnshaw JJ,
Heather BP, et al. Influence of a specialized leg ulcer service
on management and outcome. Br J Surg 2000;87:1048e56.
11 Barwell J, Davies CE, Deacon J, Harvey K, Minor J, Sassano A,
et al. Comparison of surgery and compression with compression
alone in chronic venous ulceration (ESCHAR study): randomised
controlled trial. Lancet 2004;363:1854e9.
12 Cabrera J, Redondo P, Becerra A, Garrido C, Cabrera Jr J, Garcis
Olmedo MA, et al. Ultrasound-guided injection of polidocanolmicrofoam in the management of venous leg ulcers. Arch Der-
matol 2004;140:667e73.
13 Bergan JJ, Pascarella L. Severe chronic venous insufficiency: pri-
mary treatmentwith sclerofoam. SeminVasc Surg2005;18:49e56.
14 Pascarella L, Bergan JJ, Mekenas LV. Severe chronic venous
insufficiency treated by foamed sclerosant. Ann Vasc Surg
2006;20:83e91.
15 Hertzman P, Owens R. Rapid healing of chronic venous ulcers
following ultrasound-guided foam sclerotherapy. Phlebology
2007;22:34e9.
16 Barrett JM, Allen B, Ockelford A, et al. Microfoam ultrasound-
guided sclerotherapy treatment for varicose veins in a subgroup
with diameters at the junction of 10 mm or greater compared
with a subgroup of less then 10 mm. Dermatol Surg 2004;30:
1386e90.
17 Alo`s J,CarrenoP, Lo´pezJA,EstadellaB, Serra-PratM,Marinel-lo J.
Efficacy and safety of sclerotherapy using polidocanol foam:
a controlled clinical trial. Eur J Vasc Endovasc Surg 2005;31:
101e7.
18 Frullini A, Cavezzi A. Sclerosing foam in the treatment of
varicose veins and telangiectases: history and analysis of safety
and complications. Dermatol Surg 2002;28:11e5.
19 Guex J-J, Allaert F-A, Gillet J-L, Chleir F. Immediate and
midterm complications of sclerotherapy: report of a prospective
multi-center registry of 12, 173 sclerotherapy sessions. Derma-
tol Surg 2005;31:123e8.
20 Jia X, Mowatt G, Burr JM, Cassar K, Cook J, Fraser C. Systematic
review of foam sclerotherapy for varicose veins. Br J Surg 2007;
94:925e36.
21 Michaels J, CampbellWB, Brazier JE, MacIntyre JB, Palfreyman SJ,
Ratcliffe J, et al. Randomised clinical trial, observational study
and assessment of cost-effectiveness of the treatment of varicose
veins (REACTIV trial). Health Technol Assess 2006;10.
